Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.25
CPHI's Cash to Debt is ranked higher than
51% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. CPHI: 0.25 )
CPHI' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.25

Equity to Asset 0.83
CPHI's Equity to Asset is ranked higher than
90% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. CPHI: 0.83 )
CPHI' s 10-Year Equity to Asset Range
Min: -10   Max: 0.97
Current: 0.83

-10
0.97
F-Score: 4
Z-Score: 1.23
M-Score: -3.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -72.93
CPHI's Operating margin (%) is ranked higher than
51% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. CPHI: -72.93 )
CPHI' s 10-Year Operating margin (%) Range
Min: -1932.43   Max: 49.02
Current: -72.93

-1932.43
49.02
Net-margin (%) -79.83
CPHI's Net-margin (%) is ranked higher than
50% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.37 vs. CPHI: -79.83 )
CPHI' s 10-Year Net-margin (%) Range
Min: -2983.78   Max: 43.89
Current: -79.83

-2983.78
43.89
ROE (%) -17.72
CPHI's ROE (%) is ranked higher than
54% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. CPHI: -17.72 )
CPHI' s 10-Year ROE (%) Range
Min: -14.22   Max: 64.99
Current: -17.72

-14.22
64.99
ROA (%) -15.25
CPHI's ROA (%) is ranked higher than
53% of the 816 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. CPHI: -15.25 )
CPHI' s 10-Year ROA (%) Range
Min: -337.12   Max: 43.43
Current: -15.25

-337.12
43.43
ROC (Joel Greenblatt) (%) -21.70
CPHI's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. CPHI: -21.70 )
CPHI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -305.76   Max: 76.87
Current: -21.7

-305.76
76.87
Revenue Growth (%) -24.00
CPHI's Revenue Growth (%) is ranked higher than
50% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. CPHI: -24.00 )
CPHI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 150.7
Current: -24

0
150.7
» CPHI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CPHI Guru Trades in Q3 2013

Jim Simons 171,300 sh (-3.6%)
» More
Q4 2013

CPHI Guru Trades in Q4 2013

Jim Simons 152,400 sh (-11.03%)
» More
Q1 2014

CPHI Guru Trades in Q1 2014

Jim Simons 157,900 sh (+3.61%)
» More
Q2 2014

CPHI Guru Trades in Q2 2014

Jim Simons 146,700 sh (-7.09%)
» More
» Details

Insider Trades

Latest Guru Trades with CPHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.10
CPHI's P/B is ranked higher than
100% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. CPHI: 0.10 )
CPHI' s 10-Year P/B Range
Min: 0.06   Max: 8.03
Current: 0.1

0.06
8.03
P/S 0.43
CPHI's P/S is ranked higher than
98% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.73 vs. CPHI: 0.43 )
CPHI' s 10-Year P/S Range
Min: 0.16   Max: 25
Current: 0.43

0.16
25
EV-to-EBIT -1.18
CPHI's EV-to-EBIT is ranked higher than
52% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. CPHI: -1.18 )
CPHI' s 10-Year EV-to-EBIT Range
Min: -31.1   Max: 82.2
Current: -1.18

-31.1
82.2
Shiller P/E 1.47
CPHI's Shiller P/E is ranked higher than
100% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 95.10 vs. CPHI: 1.47 )
CPHI' s 10-Year Shiller P/E Range
Min: 0.5   Max: 198.85
Current: 1.47

0.5
198.85
Current Ratio 5.81
CPHI's Current Ratio is ranked higher than
90% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. CPHI: 5.81 )
CPHI' s 10-Year Current Ratio Range
Min: 0.01   Max: 23.65
Current: 5.81

0.01
23.65
Quick Ratio 4.05
CPHI's Quick Ratio is ranked higher than
87% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. CPHI: 4.05 )
CPHI' s 10-Year Quick Ratio Range
Min: 0.01   Max: 17.34
Current: 4.05

0.01
17.34

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 0.74
CPHI's Price/Net Current Asset Value is ranked higher than
100% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. CPHI: 0.74 )
CPHI' s 10-Year Price/Net Current Asset Value Range
Min: 0.15   Max: 16.88
Current: 0.74

0.15
16.88
Price/Tangible Book 0.11
CPHI's Price/Tangible Book is ranked higher than
100% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.86 vs. CPHI: 0.11 )
CPHI' s 10-Year Price/Tangible Book Range
Min: 0.06   Max: 6.06
Current: 0.11

0.06
6.06
Price/DCF (Projected) 0.18
CPHI's Price/DCF (Projected) is ranked higher than
100% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. CPHI: 0.18 )
CPHI' s 10-Year Price/DCF (Projected) Range
Min: 0.08   Max: 4.3
Current: 0.18

0.08
4.3
Price/Median PS Value 0.26
CPHI's Price/Median PS Value is ranked higher than
99% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. CPHI: 0.26 )
CPHI' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 38.08
Current: 0.26

0.1
38.08
Earnings Yield (Greenblatt) -84.70
CPHI's Earnings Yield (Greenblatt) is ranked lower than
56% of the 794 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. CPHI: -84.70 )
CPHI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 136.5
Current: -84.7

1.2
136.5
Forward Rate of Return (Yacktman) -8.05
CPHI's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. CPHI: -8.05 )
CPHI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -35   Max: 24.1
Current: -8.05

-35
24.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:XQJ.Germany
China Pharma Holding, Inc., a Delaware corporation was incorporated on January 28, 1999 under the name 'Softstone, Inc.' On March 16, 2006; it changed its corporate name to China Pharma Holdings, Inc. The company develops, manufactures and markets pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions in the People's Republic of China (the 'PRC'). All of its operations are conducted in the PRC, where its manufacturing facilities are located. It manufactures pharmaceutical products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions and granules. All of its pharmaceutical products are sold on a prescription basis and have been approved for at least one or more therapeutic indications by the Chinese State Food and Drug Administration (the 'SFDA') based upon demonstrated safety and efficacy. At December 31, 2012, it manufactured 20 pharmaceutical products for a variety of diseases and medical indications. It markets and sells its products through 16 sales offices covering all major cities and provinces in the PRC. Its product portfolio includes both branded and generic drugs that it either developed or was developed by it in joint research efforts with its academic institutional partners or, to a lesser extent, acquired from third parties. It develops new products in-house as well as through relationships with several research institutes, including the Chinese Academy of Sciences, China University of Pharmaceuticals, Sichuan University, Chongqing Medical Industry Institute and the Military Medical Academy Basic Medical Science Institute. The Company sells its prescription drugs to hospitals and clinics through its distribution system which is comprised of 1,220 independent regional distributors. In November 2008, it purchased the patented medical formula for a cerebral/cardio-vascular indication and the manufacturing processes for that product candidate from a third party laboratory. In connection with that acquisition, it obtained the title of the patent. This patent expires in 2025. At December 31, 2012, it owned 17 registered trademarks, including marks for nine of the 20 pharmaceutical products it manufacture, including the tradenames Funalin, Fukexing, Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang and Shenkaineng, as well as marks for its AFGF logo, its HPS logo, its two HELPSON logos and four other logos.
» More Articles for AMEX:CPHI

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
3 Stocks Pushing The Drugs Industry Lower Oct 15 2014
CHINA PHARMA HOLDINGS, INC. Financials Aug 23 2014
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China Aug 18 2014
China Pharma Holdings, Inc. Reports Second Quarter 2014 Financial Results Aug 15 2014
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Aug 14 2014
CPHI to Hold Second Quarter 2014 Earnings Conference Call on Friday August 15, 2014 at 8:30 a.m. ET Aug 05 2014
China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2014 Results - Earnings Call Transcript May 15 2014
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report May 15 2014
China Pharma Holdings, Inc. Reports First Quarter 2014 Financial Results May 15 2014
CPHI to Hold First Quarter 2014 Earnings Conference Call on Thursday May 15, 2014 at 8:30 a.m. ET May 09 2014
China Pharma Holdings' CEO Discusses Q4 2013 Results - Earnings Call Transcript Mar 21 2014
Mar. 21, 2014 - China Pharma Holdings Announces Updated Dial-in Informationfor Mar 21 2014
Mar. 21, 2014 - China Pharma Holdings, Inc. Reports Full Year 2013 Financial Mar 21 2014
China Pharma Holdings Announces Updated Dial-in Information for Its Fiscal Year 2013 Earnings... Mar 21 2014
CHINA PHARMA HOLDINGS, INC. Files SEC form 10-K, Annual Report Mar 20 2014
CPHI to Hold Fiscal Year 2013 Earnings Conference Call on Friday, March 21, 2014 at 8:30 a.m. ET Mar 12 2014
4 Biotech Stocks Under $10 to Watch Feb 18 2014
China Pharma states it knows no events that caused unusual market activity Jan 16 2014
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market... Jan 16 2014
CHINA PHARMA HOLDINGS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 17 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK